Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Revvity Omics, |
RCV000186350 | SCV003829899 | likely pathogenic | Primary hyperoxaluria, type I | 2022-12-08 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003556225 | SCV004292195 | pathogenic | not provided | 2023-06-15 | criteria provided, single submitter | clinical testing | Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on AGXT protein function. ClinVar contains an entry for this variant (Variation ID: 204143). This missense change has been observed in individuals with primary hyperoxaluria type 1 (PMID: 25629080, 34082749). This variant is present in population databases (rs180177155, gnomAD 0.0009%). This sequence change replaces valine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 336 of the AGXT protein (p.Val336Asp). Experimental studies have shown that this missense change affects AGXT function (PMID: 18448374, 22529745). For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV000186350 | SCV005058638 | pathogenic | Primary hyperoxaluria, type I | 2024-03-02 | criteria provided, single submitter | clinical testing | |
Clinical Biochemistry Laboratory, |
RCV000186350 | SCV000239696 | pathogenic | Primary hyperoxaluria, type I | 2014-11-27 | no assertion criteria provided | in vitro |